Abbott Laboratories (ABT) Stock Analysis

55.0/100
Hold ✓ Halal Healthcare
Price $109.50
Market Cap $187.95B
52-Week Change -16.05%

Is ABT a good investment?

Abbott Laboratories (ABT) has a Plutrex AI rating of 55.0/100 as of November 12, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: FCF fortress of $6.757B annually — covers dividends multiple times over at a ~30-35% FCF payout ratio, supports 54-year Dividend King streak, and leaves $4.5B+ for buybacks and M&A; debt/equity of 0.58x is conservative and manageable. Main concern: VALUATION STRUCTURALLY WORSENED: PE 40.60x (up from 37.89x) and PEG 5.02x (up from 4.69x) — the stock rose +6.5% while the analyst target fell -0.8% and forward EPS growth estimates remain depressed at 7.56% next year (34% below industry 11.51%); at $109.35 with a stop at $93.00, risk/reward is approximately 1.1x — deeply inadequate; to achieve 2.5x R/R, entry must be below $97.50.

Investment Summary

Abbott Laboratories (ABT) at $109.35 is a high-quality healthcare franchise that remains materially overvalued by most rigorous fundamental measures. The stock has risen +6.5% from $102.67 since the prior report 14 days ago, while the analyst consensus target declined marginally from $123.12 to $122.14 — compressing upside from 19.9% to 11.7%. Critically, every valuation metric has WORSENED: PE expanded from 37.89x to 40.60x (+7.2%) and PEG from 4.69x to 5.02x (+7.2%), now representing a 40% premium to the Medical Devices industry average PE of 29.00x and a 26.5% premium on PEG (5.02x vs. industry 3.97x). The stock is growing forward EPS at only 7.56% next year and 8.08% over five years — 34% and 17% BELOW industry peers respectively — yet commands the valuation of a high-growth technology company. News sentiment is exceptionally strong at 97.1/100 (12 of 14 articles positive), driven by cardiovascular trial successes including the Amulet 360 VERITAS one-year data and TECTONIC trial 30-day outcomes, plus UltiSynq lead cardiac rhythm management opportunities. These catalysts are genuinely exciting and affirm Abbott's innovation pipeline, but do not resolve a PEG of 5.02x on 8% growth. FCF of $6.757B remains a bedrock strength. At current price of $109.35, with analyst target $122.14, risk/reward is approximately 1.1x (upside $12.79 vs. downside $16.35 to $93.00 stop), which is well below the 2.5x minimum. The investment case is not broken — it is simply priced for perfection at an elevated level that makes new entry unattractive.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
65/100
Growth Potential
28/100
Valuation
18/100
Profitability
65/100
Debt Management
70/100
Analyst Sentiment
72/100
Technical Momentum
42/100
Insider Confidence
62/100
News Sentiment
85/100

Fundamental Analysis

ABT's fundamentals reflect a mature, diversified healthcare company with genuine quality attributes but significant valuation distortion. Profitability: Gross margin 52.33% (vs. industry 57.23%, -8.6% gap), operating margin 15.65% (vs. industry 17.05%, -8.2% gap), net margin 9.80% (vs. industry 11.45%, -14.4% gap), ROE 9.27% (vs. industry 11.44%, -19.0% gap) — ABT underperforms on ALL four profitability dimensions. These are not catastrophic gaps but confirm the diversified model (nutrition, diagnostics, devices, established pharma) dilutes margins vs. focused device peers. Financial Health: Debt-to-equity 0.58x (vs. industry 0.504x, modest premium), cash $4.298B, FCF $6.757B — the FCF is the dominant financial strength, supporting the 54-year dividend growth streak at a ~30-35% FCF payout ratio, leaving $4.5-4.7B for buybacks and M&A. Growth: Forward EPS next year 7.56% (vs. industry 11.51%, -34.3% deficit), 5-year EPS 8.08% (vs. industry 9.70%, -16.7% deficit), historical EPS growth -43.6% (vs. industry -4.71%, catastrophic COVID diagnostics normalization). Revenue growth historical 14.5% (vs. industry 10.85%, +33.6% premium) is the lone bright spot. Valuation: PE 40.60x (vs. industry 29.00x, +40% premium), PEG 5.02x (vs. industry 3.97x, +26.5% premium) — investors pay significantly more for significantly less growth. Conservative FCF-based intrinsic value at 12-15x FCF multiple implies per-share value of $58-70, though this methodology understates the quality premium and recurring revenue characteristics. Even at a generous 18x FCF (rich for 8% growth), intrinsic value approaches ~$84-88/share — still well below $109.35. Additional metrics: PE Ratio: 40.60

News Sentiment

Abbott Laboratories is making waves in cardiovascular medicine, with a string of impressive clinical trial results putting the medical device giant back in the spotlight. The company's Amulet 360 LAA Occluder device — designed to reduce stroke risk in patients with irregular heart rhythms — posted strong one-year results in the VERITAS study, showing high success rates in closing off a troublesome heart chamber and keeping stroke rates impressively low. The data was published simultaneously in a major cardiology journal, lending it serious scientific credibility beyond typical corporate press releases. Abbott also reported strong 30-day outcomes from the TECTONIC clinical trial, another cardiovascular program that analysts say could integrate with the company's broader cardiac treatment ecosystem — from imaging to stenting. Meanwhile, the UltiSynq lead technology could give Abbott's Cardiac Rhythm Management business a meaningful boost, adding another arrow to its cardiovascular quiver. On the dividend front, Abbott continues its remarkable streak as a 55-year dividend grower — a rare 'Dividend King' status that few companies on earth can claim, and one that continues attracting income-focused investors. However, there's a cloud: the company faces potential legal/lawsuit exposure that could create financial headaches down the road. Despite the strong clinical momentum, the fundamental question for investors remains whether Abbott's exciting medical advances are already baked into a stock trading at over 40 times earnings.

Risk Assessment

PRIMARY RISK: Valuation compression risk is the dominant threat. At PE 40.60x on 8.1% EPS growth, any macro de-rating of growth multiples, a growth disappointment, or a market rotation away from defensive healthcare could compress the multiple toward the industry average of 29x — implying a price of approximately $78-80 (-27% to -29% from current). SECONDARY RISK: Lawsuit/legal exposure flagged in news analysis could create headline risk and financial drag — magnitude unclear but should be monitored. COVID-era earnings normalization cliff has already occurred (-43.6% EPS) but any recurrence in another segment (e.g., CGM competition from Dexcom, diagnostics cyclicality) could trigger another earnings reset. MITIGATION: Abbott's FCF of $6.757B provides a genuine floor — the business will not collapse at current prices. Existing holders are protected by the dividend (54-year growth streak), FCF coverage, and pipeline catalysts. The stop at $89.00 represents approximately -18.6% from $109.35 and sits near FCF-based support. New buyers should NOT enter at $109.35 — the risk/reward at current price is approximately 1.1x, well below minimum acceptable thresholds. Wait for the $94.00-$99.50 entry zone where risk/reward improves to ~2.5x.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ABT a halal stock?

Yes, Abbott Laboratories (ABT) is halal-compliant per AAOIFI standards as of the latest quarterly review.

What is Plutrex's AI rating for ABT?

Abbott Laboratories (ABT) has a Plutrex AI rating of 55.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ABT a good investment?

According to Plutrex AI, ABT has a Hold rating (55.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ABT?

US stocks like ABT can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ABT?

Plutrex AI identifies the main risks for ABT by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ABT

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ABT in ElBarake